CAS Medical Systems, Inc. (Nasdaq:CASM) today announced the presentation of a comparative study showing the superior accuracy of its FORE-SIGHT® Absolute Tissue Oximeter against other available oximeters.
Study has been presented on annual meeting of the American Society of Anesthesiologists (ASA) in Chicago, IL.
Thomas M. Patton, President and CEO of CASMED, commented:
“This comprehensive study clearly demonstrates the superiority of FORE-SIGHT technology and confirms the differences in clinical performance that our customers report. The improved accuracy of the FORE-SIGHT Oximeter can offer clinicians increased confidence to intervene appropriately in the care of their patients to prevent dangerous cerebral desaturation events.”
CASMED’s FORE-SIGHT Absolute Tissue Oximeter has been tested against the following industry’s devices:
- INVOS® 5100C (Covidien, Boulder, CO, USA)
- EQUANOX™ Model 7600 (Nonin Medical, Plymouth, MN, USA) with both EQUANOX Classic and Advance sensors
- NIRO® 200NX (Hamamatsu Photonics, Hamamatsu City, Japan).
The precision of the FORE-SIGHT Oximeter was reported as a standard deviation from an invasive reference and was the lowest at 3.92%, compared to a standard deviation of 9.72% for the INVOS 5100C.
Please note that ASA and SNACC annual meetings draw over 11,000 health care professionals from around the world seeking information on the latest products, services and technologies useful in the practice of anesthesia.
CAS Medical Systems, Inc.
44 East Industrial Road
Branford, Connecticut 06405
Tel: (800) 227-4414
Fax: (203) 488-9438
http://www.casmed.com/
CASMED designs, manufactures and markets innovative technologies and monitors that deliver accurate, reliable patient data. For over 25 years our reputation for high quality products has remained consistent, and our products are trusted by clinicians worldwide.